Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks
1. Quest Diagnostics surpassed Q2 2025 earnings expectations with 15.2% sales growth. 2. Guidance for 2025 revenue increased to $10.80-$10.92 billion, above consensus. 3. Potential financial challenges from tariffs and PAMA impact loom over future results. 4. Company experiencing productivity gains from automation, boosting operational efficiency. 5. Analyst firms maintain positive outlook on stock, rating it Outperform.